Skip to content

hAM for Inferior RRD

Prospective Study on the Use of Human Amniotic Membrane (hAM) in the Treatment of Inferior Rhegmatogenous Retinal Detachment (RRD)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07081945
Enrollment
50
Registered
2025-07-24
Start date
2025-08-01
Completion date
2026-07-31
Last updated
2025-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhegmatogenous Retinal Detachment

Brief summary

The objective of the study is to evaluate the efficacy of using hAM patches over the retina to seal inferior retinal breaks. The researchers will evaluate whether hAM patch-assisted vitrectomy improves surgical success rate of retinal reattachment.

Detailed description

Rhegmatogenous retinal detachments (RRDs) with inferior retinal breaks (IRB-RRD) still remains a challenge with relatively high risk of primary surgical failure and recurrent RRDs. Actually, the single-operation success rate for inferior RRD ranges from 60 % to 90 % as reported. Human amniotic membrane (hAM) and has been reported to be safe for intraocular use, such as macular hole and ocular open globe injury. Researchers previously reported a 'sandwich' technique for flattening and positioning large-sized hAM patches over the retina, which allowed surgeons to select the optimal hAM size intraoperatively based on surgical need, and thus expanding the application of hAM in RRD. Researchers had demonstrated that covering the exposed retinal pigment epithelium (RPE) with a large-size hAM graft effectively prevented postoperative proliferative vitreoretinopathy (PVR) by the 'sandwich' technique. This study will include 50 patients with IRB-RRD, who will be treated with hAM patch-assisted vitrectomy, in which hAM patches will be used to seal inferior retinal breaks over the retina after complete vitrectomy. Then researchers will conduct no less than 6 months follow-up and evaluate whether hAM patch-assisted vitrectomy improves surgical success rate of retinal reattachment.

Interventions

DEVICEhAM

The hAM stands for human amniotic membrane, which was used to seal inferior retinal breaks after complete vitrectomy.

Sponsors

Eye & ENT Hospital of Fudan University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Subjects having given free and informed consent to take part in the study. 2. Subjects between 18 and 70 years old. 3. Subjects suffering RRD (both primary and recurrent RRDs) with at least one of these conditions: 1. inferior retinal breaks between 4- and 8-o'clock within the detached area regardless of PVR grade; 2. requiring retinotomy inferiorly between 4- and 8-o'clock (due to severe inferior PVR or inferior retinal shortening).

Exclusion criteria

1. Subjects with RRD with only anterior retina breaks or dialysis and meet the indications for scleral buckling surgery. 2. Subjects with RRD whose retinal breaks located between the 4- and 8-o'clock positions and are not involved in the detached area. 3. Subjects with pre-existing serious eye diseases (corneal ulcers, glaucoma, uveitis, etc). 4. History of epilepsy or serious psychiatric diseases. 5. Other conditions that the researcher found improper to be included into this study.

Design outcomes

Primary

MeasureTime frameDescription
Retinal reattachment rateFrom enrollment to the end of the 6-month follow-up period.The percentage of patients who achieved retinal reattachment after undergoing hAM patch-assisted vitrectomy during the 6-month follow-up period.
Visual acuity improvementFrom enrollment to the end of the 6-month follow-up period.The visual acuity improvement 6 months after the surgical procedure measured by Snellen chart.

Countries

China

Contacts

Primary ContactZhongcui Sun, PhD.
zhongcui.sun@aliyun.com+8621-64377134-2501

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026